8 completed, 6 terminated, 2 not yet recruiting, 1 recruiting. 19 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 8, Terminated 6, Not yet recruiting 2, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 7 | Terminated 4, Completed 1, Not yet recruiting 1, Unknown 1 |
Follow Lomustine: new trials by email Literature Review of Lomustine trials Research Report on Lomustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations Vorasidenib, Lomustine - Recurrent Glioma, IDH-mutant Gliomas | Phase 1 | Not yet recruiting | Megan Mantica | 36 | 2026-11-30 | 2026-10-22 |
| A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers AL58805, AL3818, Temozolomide (TMZ) - Endometrial Neoplasms, Ovarian Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | 138 | 2026-09-01 | 2026-09-10 |
| Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma Laser interstitial thermal therapy, Lomustine - Glioblastoma | Phase 1 | Recruiting | University of California, Davis | 25 | 2025-10-01 | 2026-09-28 |
| Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression Onfekafusp alfa, Lomustine - Glioblastoma | Phase 1 | Withdrawn | Philogen S.p.A. | 2022-06-01 | 2024-04-08 | |
| A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression L19TNF, Lomustine - Glioblastoma | Phase 1 / Phase 2 | Unknown | Philogen S.p.A. | 142 | 2021-02-19 | 2024-04-08 |
| A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma Selinexor, Temozolomide (TMZ), Lomustine (CCNU) - Glioblastoma Multiforme | Phase 1 / Phase 2 | Terminated | Karyopharm Therapeutics Inc | 74 | 2020-06-08 | 2024-12-16 |
| A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer Temozolomide, conformal brain radiation therapy, Nivolumab - Newly Diagnosed High Grade Glioma | Phase 1 | Completed | Saint John's Cancer Institute | 49 | 2018-03-01 | 2023-11-08 |
| Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects VBI-1901, Carmustine, Lomustine - Glioblastoma Multiforme | Phase 1 / Phase 2 | Terminated | VBI Vaccines Inc. | 70 | 2017-12-06 | 2026-05-08 |
| Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM) USL311, Lomustine - Solid Tumors (Phase 1), Relapsed/Recurrent GBM (Phase 2) | Phase 1 / Phase 2 | Terminated | Proximagen, LLC | 26 | 2016-04-01 | 2021-07-23 |
| Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma CTO, Lomustine - Malignant Glioma (WHO Grade III or IV) | Phase 1 | Terminated | Annick Desjardins | 9 | 2014-05-01 | 2016-08-04 |
| Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme buparlisib, carboplatin, lomustine - Recurrent Glioblastoma Multiforme | Phase 1 | Completed | Novartis Pharmaceuticals | 35 | 2014-02-28 | 2020-12-09 |
| A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain Brain radiotherapy (WBRT alone, SRT/SRS alone or WBRT plus SRT/SRS), Lomustine, Liposomal cytarabine - Leptomeningeal Metastasis From Malignant Melanoma | Phase 1 | Terminated | University Hospital, Bonn | 1 | 2012-03-01 | 2016-04-19 |
| Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM) Dasatinib, Lomustine - Glioblastoma | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 28 | 2009-10-01 | 2012-08-31 |
| Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults maintenance chemotherapy (vincristin, cisplatin and CCNU), Radiotherapy - Medulloblastoma | Phase 1 / Phase 2 | Completed | University of Regensburg | 33 | 2009-01-01 | 2020-03-31 |
| Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour Cediranib, Lomustine - Recurrent Glioblastoma, Brain Tumor | Phase 1 | Completed | AstraZeneca | 20 | 2007-09-01 | 2009-11-25 |
| Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients Lomustine, Temozolomide, Thalidomide - Brain Neoplasms, Melanoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 17 | 2006-02-09 | 2018-11-14 |
| A Dose-Escalation Study in Participants With Recurrent Malignant Glioma LY2157299, Lomustine - Glioma | Phase 1 | Completed | Eli Lilly and Company | 66 | 2005-12-15 | 2024-11-07 |
| Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma lomustine, temozolomide - Brain Tumor, Central Nervous System Tumor | Phase 1 | Completed | Children's Oncology Group | 32 | 2000-11-01 | 2014-02-13 |
| Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors filgrastim, gene therapy, lomustine - Bone Marrow Suppression, Brain and Central Nervous System Tumors | Phase 1 | Completed | Indiana University | 10 | 2000-02-01 | 2015-03-25 |
Glioblastoma (11) · Brain Neoplasms (5) · Glioma (4) · Neoplasms (4) · Astrocytoma (2) · Central Nervous System Neoplasms (2) · Medulloblastoma (2) · Drug-Related Side Effects and Adverse Reactions (1) · Endometrial Neoplasms (1) · Ependymoma (1) · Familial ependymoma (1) · Gliosarcoma (1) · Lymphoma, Follicular (1) · Melanoma (1) · Neuroectodermal Tumors (1)
Philogen S.p.A. (2) · Advenchen Pharmaceuticals, LLC. (1) · Annick Desjardins (1) · AstraZeneca (1) · Bristol-Myers Squibb (1) · Children's Oncology Group (1) · Eli Lilly and Company (1) · Indiana University (1) · Karyopharm Therapeutics Inc (1) · M.D. Anderson Cancer Center (1) · Megan Mantica (1) · Novartis Pharmaceuticals (1) · Proximagen, LLC (1) · Saint John's Cancer Institute (1) · University Hospital, Bonn (1)
United States (14) · Canada (3) · France (3) · Germany (3) · Spain (3) · Switzerland (3) · Australia (2) · Italy (2) · Netherlands (2) · Belgium (1) · New Zealand (1) · Puerto Rico (1) · United Kingdom (1)
Andrew B Lassman, MD (1) · Annick Desjardins, MD, FRCPC (1) · Carlos K Matsuoka, MD (1) · Francisco Diaz-Mitoma, MD (1) · James Croop, MD, PhD (1) · Jane Robertson (1) · Judy Chen (1) · Martin Glas, PD Dr. (1) · Megan Mantica, MD (1) · Nicholas E. Papadopoulos, MD (1) · Orwa Aboud, MD, PhD (1) · Peter Hau, MD (1)
PMID 18497327, PMID 32665311, PMID 37224228, PMID 39572979
2009 (1), P30CA093373 (1)